Navigation Links
Iomai Announces Year-End 2007 Financial Results and Business Progress
Date:3/6/2008

benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.

Some matters discussed in this press release constitute "forward-looking statements" that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about potential commercialization of a vaccine that could be mailed and self-applied, the ability of Iomai to enter into a partnering deal, conducting a Phase 3 trial of Iomai's travelers' diarrhea vaccine, and the sufficiency of existing cash and government contract revenues to fund operations into the third quarter of 2008. Applicable risks and uncertainties include, among others, that the clinical results may not support regulatory approval to commercialize any Iomai product candidate or the mailing and self-administration of any product that does gain approval, both of which will depend on the outcome of additional clinical trials and analysis by regulatory authorities of data Iomai submits; assessments by third-parties of the potential commercial value of the TCI technology, potential partners may determine to wait for additional clinical data prior to partnering or may be unwilling to partner on terms and conditions Iomai deems acceptable; Iomai's intellectual property position, and the market potential of Iomai's product candidates; future clinical trials may
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6
2. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
3. Iomai to Announce Third Quarter 2007 Financial Results and Host Webcast on Tuesday, November 13
4. Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers Diarrhea Patch at Keystone Conference
5. Iomai CEO to Speak at Natixis Bleichroeder Hidden Gems Conference on Monday
6. Dragon announces new product launch; increase in annual production output capacity
7. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
8. China Yingxia International Announces Q4 and FY 2007 Estimates
9. Bristol-Myers Squibb Announces Dividend
10. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
11. Maxygen Announces Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... Markets Inc. (OTCQX: PINK), the financial information and ... quotation and trading system in the U.S. OTC ... (OTCQX: CRMMF, TSX.V: CRM), a Canadian-based medical technology ... highest tier, OTCQX®. (Logo:   http://photos.prnewswire.com/prnh/20090708/NY43125LOGO ...
... DIEGO, Aug. 17 MabVax Therapeutics, Inc., a privately ... of vaccine and antibody based therapies to address the ... it has received a Small Business Innovation Research Grant ... agency,s Streamlined Non-competing Award Procedures (SNAP). Under the SNAP ...
... of only two studies of its kind, a study from ... School of Graduate Biomedical Sciences at Tufts demonstrates that non-viral ... eye disease and preserve vision. The team developed nanoparticles to ... mice temporarily retained more eyesight than controls. The study, published ...
Cached Biology Technology:CRH Medical Corp. Joins OTCQX 2CRH Medical Corp. Joins OTCQX 3MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute 2MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute 3Breakthrough gene therapy prevents retinal degeneration 2
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... security consultant, Apollo Robbins for the 2015 ... Apollo Robbins will be ... , 2015, demonstrating some of his famous theft techniques ...
(Date:12/22/2014)... 2014  The 2014 Holiday Season may be ... Acuity Market Intelligence reports that the long anticipated ... Acuity forecasts that intensifying demand for smart phones, ... will drive a global market of 2.5 billion ... 2020.   According to Maxine ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... A new paper published online in Nature ... type of lung cancer may one day benefit from targeted ... Squamous cell lung cancer kills more people each ... to lung adenocarcinoma in the number of deaths it causes. ...
... extensive forest death triggered by hot and dry climatic ... Forest mortality due to drought and heat stress is ... has focused on isolated incidents of forest mortality, little ... die-offs. A new analysis of the current literature on ...
... applied fertilizer to newly placed sod may result in nutrient ... best time to apply fertilizer and what kind is the ... is a team of scientists from Texas A&M AgriLife Research: ... management; Dr. Ben Wherley, assistant professor of turfgrass science and ...
Cached Biology News:New potential targets discovered for treating squamous cell lung cancers 2New potential targets discovered for treating squamous cell lung cancers 3Forest mortality and climate change: The big picture 2Forest mortality and climate change: The big picture 3Turf study to monitor runoff, establish fertilizer management practices 2
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by incubation of linoleic acid with ... to inhibit the adhesion of tumor cells to ...
... Mass Standards Kit includes reagents that can ... instrument parameters, and calibrate the mass scale ... designed for use with the 4700 Proteomics ... Standards in the kit require minimal preparation ...
...
Biology Products: